Erratum to: End-of-life costs of medical care for advanced stage cancer patients (Vojnosanit Pregl, 2015; 72(4), 334–341 DOI:10.2298/VSP1504334K);End-of-life costs of medical care for advanced stage cancer patients;Medicinski troškovi palijativne nege bolesnika sa karcinomom

Vojnosanitetski Pregled

Volumn 72, Issue 4, 2015, Pages 334-341

  Kovačević, Aleksandra ^a,b   Dragojević Simić, Viktorija ^a,b   Rančić, Nemanja ^a,b   Jurišević, Milena ^c   Gutzwiller, Florian ^d   Matter Walstra, Klazien ^d   Jakovljević, Mihajlo ^c  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b University of Defence ^*  (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antibodies; Carcinoma; Drug therapy; Health care costs; Monoclonal; Serbia; Terminal care

Indexed keywords

MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTPATIENT CARE; RETROSPECTIVE STUDY; SERBIA; TERMINAL CARE; CANCER STAGING; ECONOMICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SERBIA; TERMINAL CARE;

EID: 84920288589     PISSN: 00428450     EISSN: 24060720     Source Type: Journal    
DOI: 10.2298/VSP1504334K     Document Type: Erratum

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. World Health Organization. Global Burden of the disease 2004 update. Geneva: World Health Organization; 2008.
3. World Health Organization. World health statistics 2013. Geneva: World Health Organization; 2013.
4. Uyl-de Groot C. Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42(17): 2862-6.
5. Murthy RS, Lakshminarayana R. Mental health consequences of war: a brief review of research findings. World Psychiatry 2006; 5(1): 25-30.
6. Papathanasiou K, Gianoulis C, Tolikas A, Dovas D, Koutsos J, Frag-kedakis N, et al. Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neo-plasia (CIN) and invasive cancer of the cervix in Greece. Clin Exp Obstet Gynecol 2005; 32(1): 58-60.
7. Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer 2013; 13: 18.
8. Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2012. Belgrade: Institute of Public Health of Serbia; 2013.
9. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Georgia: American Cancer Society; 2013.
10. Jason H. Experts debate if the cost of end-of-life cancer care is too high. HemOnc Today [cited 2009 September 10]. Avail-able from: www.healio.com ›
11. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic bur-den of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14(12): 1165-74.
12. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14(2): 153-9.
13. Arnold RG, Kotsanos JG. Panel 3: methodological issues in con-ducting pharmacoeconomic evaluations-retrospective and claims database studies. Value Health 1999; 2(2): 82-7.
14. Jakovljevic M, Rankovic A, Rancic N, Jovanovic M, Ivanovic M, Ga-jovic O, et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe-A Retrospective Analysis from Serbia. Value Health Reg 2013; 2(2): 218-25.
15. Milijus D, Zivkovic S, Bozic Z. Cancer incidence and mortality in central Serbia. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”; 2012.
16. Leblanc TW, Abernethy AP. Defining quality, disseminating evi-dence, and enforcing guidelines for cancer treatment. Virtual Mentor 2013; 15(8): 713-7.
17. Institute of Public Health of Serbia. Cancer incidence and mortality in Serbia 2010. Belgrade: Institute of Public Health of Serbia; 2012.
18. Šipetić T. Marketing and consumption of medicinal products for human use in 2010. Belgrade: Agencija za lekove i medicin-ska sredstva Srbije; 2011. (Serbian)
19. Šipetić T. Marketing and consumption of medicinal products for human use in 2011. Belgrade: Agencija za lekove i medicin-ska sredstva Srbije; 2012. (Serbian)
20. Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2011. Belgrade: Institute of Public Health of Serbia; 2012.
21. Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2010. Belgrade: Institute of Public Health of Serbia; 2011.
22. Earle C, Neville B, Landrum MB, Ayanian J, Block S, Weeks J. Trends in the Aggressiveness of Cancer Care Near the End of Life. J Clin Oncol 2004; 22(2): 315-21.
23. Rankovic A, Rancic N, Jovanovic M, Ivanovic M, Gajovic O, Lazic Z, et al. Impact of imaging diagnostics on the budget-Are we spending too much? Vojnosanit Pregl 2013; 70(7): 709-11.
24. Zweifel P. The Grossman model after 40 years. Eur J Health Econ 2012; 13(6): 677-82.
25. Radovanovic A, Dagovic A, Jakovljevic M. Economics of cancer re-lated medical care: estimates worldwide and available domestic evidence. Arch Oncol 2011; 19(3-4): 59-63.
26. Autier P, Ouakrim A, Malvezzi M, Bleiberg H, Jenkins M, Boniol M, et al. Trends in colorectal cancer mortality and screening activities in European countries. Eur J Cancer 2013; 49(2 Suppl): S299.
27. Marsland T, Robbins G, Marks A, Cassell R, Philips Green D, King K. Reducing Cancer Costs and Improving Collaboration With Payers: A Proposal From the Florida Society of Clinical On-cology. J Oncol Pract 2010; 6(5): 265-9.
28. Huskamp HA, Keating NL, Malin JL, Zaslavsky AM, Weeks JC, Earle CC, et al. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 2009; 169(10): 954-62.
29. Kaló Z, Landa K, Doležal T, Vokó Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care (Engl) 2012; 21(4): 442-9.